Inclusion criteria included the presence of HBsAg in serum for at least 6 months; presence of HBeAg; absence of hepatitis Bs antibody (anti-HBs); absence of hepatitis Be antibody (anti-HBe); ALT ...
Background: The duration of protection after hepatitis B vaccination of infants is unknown. Methods: We determined antibody to hepatitis B surface antigen (anti-HBs) at 4-13 years of age in 363 ...
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback